Cumulative incidence of regimen failure 22.8 percent in the cabotegravir-rilpivirine group versus 41.2 percent in the standard-care group by week 48
FRIDAY, Feb. 27, 2026 (HealthDay News) — Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in persons with human immunodeficiency virus (HIV) and medication adherence challenges, according to a study published online Feb. 18 in the New England Journal of Medicine.
Aadia I. Rana, M.D., from the University of Alabama at Birmingham, and colleagues enrolled 453 persons with HIV who had inadequate adherence to ART (a persistent HIV-1 RNA level of >200 copies per milliliter or loss to follow-up) to 24 weeks of adherence support, conditional economic incentives, and standard care with oral ART as part of step 1. Then, in step 2, the 306 participants achieving an HIV-1 RNA level of ≤200 copies per milliliter were randomly assigned to continue standard care (154 participants) or switch to monthly injections of long-acting cabotegravir plus rilpivirine with or without oral lead-in therapy (152 participants).
The researchers reported that step 2 randomization was stopped early on the basis of the superiority of cabotegravir-rilpivirine to standard care at a prespecified analysis. By week 48, the cumulative incidence of regimen failure was 22.8 percent in the cabotegravir-rilpivirine group and 41.2 percent in the standard-care group. For adverse events, the cumulative incidence was 43.5 percent in the cabotegravir-rilpivirine group versus 42.4 percent in the standard-care group. Two participants in each group developed resistance-associated mutations with confirmed virologic failure.
“These findings have the potential to validate a long-acting approach for this additional group of patients and could make a significant difference to people living with HIV and our goal of ending the epidemic,” Kimberly Smith, M.D., head of research & development at ViiV Healthcare, said in a statement.
Several authors disclosed ties to ViiV Healthcare, the maker of cabotegravir-rilpivirine.
Outpatient Benzodiazepine Treatment Down in U.S. Adults From 2018 to 2022 
Diltiazem Linked to Increased Risk for Bleeding Complications in A-Fib 
Perioperative Enfortumab Vedotin + Pembrolizumab Tied to Improved Outcomes With Bladder Cancer 
Umeclidinium-Vilanterol Tied to Better Outcomes Than Other LAMA-LABA Inhalers in Symptomatic COPD 
Oxybutynin Beats Placebo for Reducing ADT-Linked Hot Flashes in Prostate Cancer 
Sodium-Glucose Cotransporter 2 Inhibitors Tied to Lower Use of Gout Medications 
Use of Meds for Mental Health Up in Children, Young Adults From 2001 to 2020 
Secondary Cardiovascular Disease Prevention With Semaglutide at Cash Price Is Cost-Effective 
